Evidence map›Paper›PMID 31628191›Full record

ArticleThe Journal of biological chemistry2019

GAIN domain-mediated cleavage is required for activation of G protein-coupled receptor 56 (GPR56) by its natural ligands and a small-molecule agonist.

Beika Zhu, Rong Luo, Peng Jin, Tao Li, Hayeon C Oak, Stefanie Giera, Kelly R Monk, Parnian Lak, Brian K Shoichet, Xianhua Piao

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 69 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Adhesion G protein-coupled receptors.Pharmacological reviews · 2026
    Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Ligands and Beyond: Mechanosensitive Adhesion GPCRs.Pharmaceuticals (Basel, Switzerland) · 2022
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Beika ZhuEli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, Weill Institute of Neuroscience, University of California, San Francisco, California 94143.ORCID 0000-0003-2210-2772
Rong LuoDepartment of Medicine, Children's Hospital and Harvard Medical School, Boston, Massachusetts 02115.
Peng JinEli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, Weill Institute of Neuroscience, University of California, San Francisco, California 94143.ORCID 0000-0003-3106-5803
Tao LiEli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, Weill Institute of Neuroscience, University of California, San Francisco, California 94143.
Hayeon C OakEli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, Weill Institute of Neuroscience, University of California, San Francisco, California 94143.
Stefanie GieraDepartment of Medicine, Children's Hospital and Harvard Medical School, Boston, Massachusetts 02115.
Kelly R MonkVollum Institute, Oregon Health and Science University, Portland, Oregon 97239.
Parnian LakDepartment of Pharmaceutical Chemistry and Quantitative Biology Institute, University of California, San Francisco, California 94143.
Brian K ShoichetDepartment of Pharmaceutical Chemistry and Quantitative Biology Institute, University of California, San Francisco, California 94143.
Xianhua PiaoEli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, Weill Institute of Neuroscience, University of California, San Francisco, California 94143 xianhua.piao@ucsf.edu.
University of California, San Francisco · USBoston Children's Hospital · USQB3 · USOregon Health & Science University · US

Funding

Adhesion G Protein-Coupled Receptors in CNS Development and RegenerationR01NS094164 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PIAO, XIANHUA · 2015 to 2025
$4.5M
MOLECULAR AND GENETIC ANALYSIS OF GPR126 IN PERIPHERAL NERVE.R01NS079445 · NINDS · WASHINGTON UNIVERSITY · PI MONK, KELLY R · 2012 to 2020
$3.1M
Glial Mechanisms Of Developmental Synapse RefinementR01NS108446 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PIAO, XIANHUA · 2018 to 2022
$2.9M
Adhesion GPCR interactome landscaping by in vivo biotinylation proteomicsR21NS108312 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PIAO, XIANHUA · 2018 to 2019
$448k
NINDS NIH HHS R01 NS079445NINDS NIH HHS R01 NS094164NINDS NIH HHS R01 NS108446NINDS NIH HHS R21 NS108312
6 · The paper itself

Abstract

Adhesion G protein-coupled receptors (aGPCRs) represent a distinct family of GPCRs that regulate several developmental and physiological processes. Most aGPCRs undergo GPCR autoproteolysis-inducing domain-mediated protein cleavage, which produces a cryptic tethered agonist (termed Stachel (stinger)), and cleavage-dependent and -independent aGPCR signaling mechanisms have been described. aGPCR G1 (ADGRG1 or G protein-coupled receptor 56 (GPR56)) has pleiotropic functions in the development of multiple organ systems, which has broad implications for human diseases. To date, two natural GPR56 ligands, collagen III and tissue transglutaminase (TG2), and one small-molecule agonist, 3-α-acetoxydihydrodeoxygedunin (3-α-DOG), have been identified, in addition to a synthetic peptide, P19, that contains seven amino acids of the native Stachel sequence. However, the mechanisms by which these natural and small-molecule agonists signal through GPR56 remain unknown. Here we engineered a noncleavable receptor variant that retains signaling competence via the P19 peptide. We demonstrate that both natural and small-molecule agonists can activate only cleaved GPR56. Interestingly, TG2 required both receptor cleavage and the presence of a matrix protein, laminin, to activate GPR56, whereas collagen III and 3-α-DOG signaled without any cofactors. On the other hand, both TG2/laminin and collagen III activate the receptor by dissociating the N-terminal fragment from its C-terminal fragment, enabling activation by the Stachel sequence, whereas P19 and 3-α-DOG initiate downstream signaling without disengaging the N-terminal fragment from its C-terminal fragment. These findings deepen our understanding of how GPR56 signals via natural ligands, and a small-molecule agonist may be broadly applicable to other aGPCR family members.

Indexed as

AnimalsCells, CulturedDose-Response Relationship, DrugFemaleHEK293 CellsHumansLigandsLimoninsMaleMiceMice, KnockoutReceptors, G-Protein-CoupledSmall Molecule LibrariesStructure-Activity Relationship3-alpha-acetoxydihydrodeoxygeduninADGRG1 protein, humanLigandsLimoninsReceptors, G-Protein-CoupledSmall Molecule Libraries3-α-DOGADGRG1/GPR56cell signalingcollagendevelopmentGPCR autoproteolysis-inducing (GAIN) domainG protein–coupled receptor (GPCR)sheddingtethered agonistTG2

Identifiers

PMID31628191
PMCPMC6916468
OpenAlexW2980679484

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.